FDA submission Oct 3, 2022 Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Aug 16, 2022 Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia Aug 2, 2022 Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jun 1, 2022 Iovance Biotherapeutics Shares New TIL Data in Melanoma, Projects Lifileucel FDA Filing in August Premium May 27, 2022 BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL May 23, 2022 Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer Dec 22, 2021 Allarity Therapeutics Submits NDA for Dovitinib for Treating Certain Renal Cancer Patients Nov 30, 2021 AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer Nov 17, 2021 Mirati Therapeutics Submits IND to FDA for PRMT5 Inhibitor in MTAP-Deleted Cancers Oct 28, 2021 Novartis Seeking FDA, EMA Kymriah Approval for Follicular Lymphoma Oct 25, 2021 Drugmakers Face Uncertain Regulatory Pathways in Bringing Novel Cell Therapies to Market Premium Oct 1, 2021 Gilead Files for FDA Approval of Second-Line Yescarta for Large B-Cell Lymphoma Aug 17, 2021 Tempus Submits PMA Application for Tumor Profiling Assay to FDA Jul 26, 2021 FDA Accepts NDA for Aadi Bioscience's mTOR Inhibitor Fyarro in PEComa Jul 16, 2021 Merck Updates Results From Early-Stage TNBC Keytruda Study On Path to Second FDA Approval Bid Premium Jul 6, 2021 FDA Accepts Allarity Therapeutics' PMA for Dovitinib Companion Test Jun 28, 2021 Gilead's Yescarta Improves Large B-Cell Lymphoma Patients' Outcomes Over Standard Care in Zuma-7 Jun 10, 2021 Amid FDA Holdup, Iovance's TIL Therapy Shows Strong Performance in Advanced Melanoma Trials Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
